Published in Clin Cancer Res on June 15, 2007
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res (2011) 1.82
The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr Opin Immunol (2008) 1.51
Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol (2008) 1.48
Direct and immune-mediated cytotoxicity of interleukin-21 contributes to antitumor effects in mantle cell lymphoma. Blood (2015) 1.40
Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol (2009) 1.22
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
Granule exocytosis mediates immune surveillance of senescent cells. Oncogene (2012) 1.14
Maintenance of intestinal Th17 cells and reduced microbial translocation in SIV-infected rhesus macaques treated with interleukin (IL)-21. PLoS Pathog (2013) 1.12
Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol (2011) 1.09
Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology (2007) 1.03
Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol (2011) 0.99
Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res (2008) 0.94
Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) (2014) 0.94
Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J Clin Invest (2015) 0.93
IL-21 augments natural killer effector functions in chronically HIV-infected individuals. AIDS (2008) 0.93
Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol (2008) 0.91
Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation. J Immunother (2012) 0.90
A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res (2012) 0.89
Interleukin-21 can efficiently restore impaired antibody-dependent cell-mediated cytotoxicity in patients with oesophageal squamous cell carcinoma. Br J Cancer (2009) 0.89
Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy (2011) 0.88
Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines. PLoS One (2010) 0.87
An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers. PLoS Comput Biol (2011) 0.85
Lack of IL-21 signal attenuates graft-versus-leukemia effect in the absence of CD8 T-cells. Bone Marrow Transplant (2011) 0.85
Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells. BMC Immunol (2009) 0.85
Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer (2014) 0.83
IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res (2015) 0.83
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer. Br J Cancer (2012) 0.81
Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am J Immunol (2009) 0.81
The role of interleukin-21 in HIV infection. Cytokine Growth Factor Rev (2012) 0.81
Comparison of vascular leak syndrome in mice treated with IL21 or IL2. Comp Med (2013) 0.80
Interleukin-21 accelerates thymic recovery from glucocorticoïd-induced atrophy. PLoS One (2013) 0.80
Multivariate evaluation of pharmacological responses in early clinical trials - a study of rIL-21 in the treatment of patients with metastatic melanoma. Br J Clin Pharmacol (2010) 0.79
Extending the lifespan and efficacies of immune cells used in adoptive transfer for cancer immunotherapies-A review. Oncoimmunology (2015) 0.78
An HIV-1 envelope glycoprotein trimer with an embedded IL-21 domain activates human B cells. PLoS One (2013) 0.78
Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens. J Immunol (2014) 0.77
IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clin Cancer Res (2016) 0.77
Effect of interleukin 21 and its receptor on CD8(+) T cells in the pathogenesis of diffuse large B-cell lymphoma. Oncol Lett (2014) 0.76
IL-21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma. Clin Transl Immunology (2013) 0.76
Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor. Oncoimmunology (2017) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 6.93
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell (2007) 4.59
Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol (2006) 4.51
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol (2006) 2.81
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol (2003) 2.68
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol (2012) 2.45
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 2.30
Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets. Blood (2002) 2.30
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell (2012) 2.29
Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol (2004) 1.88
Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol (2005) 1.85
An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest (2012) 1.79
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys (2003) 1.73
Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res (2009) 1.72
Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol (2002) 1.67
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother (2009) 1.66
MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO J (2004) 1.64
The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res (2008) 1.64
UBF levels determine the number of active ribosomal RNA genes in mammals. J Cell Biol (2008) 1.57
Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood (2004) 1.54
Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res (2009) 1.52
CT-X antigen expression in human breast cancer. Proc Natl Acad Sci U S A (2009) 1.51
AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. Sci Signal (2011) 1.49
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood (2006) 1.47
BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem (2004) 1.45
Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res (2004) 1.41
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway. Blood (2004) 1.39
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res (2013) 1.38
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res (2009) 1.32
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol (2007) 1.29
Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell (2013) 1.28
Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers. Cancer Res (2006) 1.27
Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nat Rev Cancer (2013) 1.26
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res (2012) 1.25
Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. Blood (2003) 1.25
Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol (2006) 1.25
In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer. Mol Cancer Ther (2011) 1.23
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res (2010) 1.22
IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother (2008) 1.22
The effect of neurogenin3 deficiency on pancreatic gene expression in embryonic mice. J Mol Endocrinol (2006) 1.20
BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res (2013) 1.18
Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev (2011) 1.16
Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res (2009) 1.16
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 1.15
BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol (2013) 1.12
Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci U S A (2004) 1.11
Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood (2008) 1.11
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci U S A (2002) 1.11
Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics (2009) 1.09
IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes. J Immunol (2007) 1.09
Identification of novel type 1 diabetes candidate genes by integrating genome-wide association data, protein-protein interactions, and human pancreatic islet gene expression. Diabetes (2012) 1.09
Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother (2007) 1.09
The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res (2013) 1.08
Distinctive localization of antigen-presenting cells in human lymph nodes. Blood (2008) 1.08
ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J Immunol (2009) 1.08
Activin-A: a novel dendritic cell-derived cytokine that potently attenuates CD40 ligand-specific cytokine and chemokine production. Blood (2007) 1.06
IL-1 beta enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J Immunol (2002) 1.06
IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol (2002) 1.06
Adjuvant effect of di-n-butyl-, di-n-octyl-, di-iso-nonyl- and di-iso-decyl phthalate in a subcutaneous injection model using BALB/c mice. Pharmacol Toxicol (2002) 1.06
Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood (2002) 1.05
Rational approaches to human cancer immunotherapy. J Leukoc Biol (2003) 1.05
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res (2014) 1.05
Structure determination of T cell protein-tyrosine phosphatase. J Biol Chem (2002) 1.05
Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res (2011) 1.04
Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1. Immunol Cell Biol (2006) 1.03
ATP gradients inhibit the migratory capacity of specific human dendritic cell types: implications for P2Y11 receptor signaling. Blood (2003) 1.03
Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology (2007) 1.03
Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res (2007) 1.03
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood (2013) 1.02
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer (2013) 1.02
An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res (2005) 1.02
The mTORC1 inhibitor everolimus prevents and treats Eμ-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov (2012) 1.01
A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep (2013) 1.01